Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.55 |
| ▸ | CNR2 | P34972 | 8/20 | 0.55 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046753 | 0.85 | CNR1 (0.55) | CNR1CNR2P2RX7 | |
| SCHEMBL13046982 | 0.84 | CNR2 (0.45) | CNR1CNR2MRGPRX1HTR4 | |
| SCHEMBL13046734 | 0.84 | PARP1 (0.47) | CNR1CNR2P2RX7 | |
| SCHEMBL13046727 | 0.84 | HPGD (0.48) | CNR1CNR2P2RX7 | |
| SCHEMBL13046829 | 0.84 | CNR1 (0.40) | CNR1CNR2P2RX7 | |
| SCHEMBL13046735 | 0.83 | SMN1; SMN2 (0.42) | CNR1CNR2P2RX7 | |
| SCHEMBL13047115 | 0.82 | CNR1 (0.42) | CNR1CNR2MRGPRX1HTR4TAS2R8 | |
| SCHEMBL13046806 | 0.82 | P2RX7 (0.42) | CNR1CNR2P2RX7 | |
| SCHEMBL1590551 | 0.81 | CNR1 (0.42) | CNR1CNR2MRGPRX1HTR4TAS2R8 | |
| SCHEMBL1590806 | 0.81 | CNR1 (0.42) | CNR1CNR2MRGPRX1HTR4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CNR1 49/4885CNR2 42/4885MRGPRX1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.